NYB (NYB Holdings) Pretax Margin %: 1,576.47% (As of Sep. 2025)


What is NYB Holdings Pretax Margin %?

NYB Holdings NYB Pretax Margin % is 1,576.47% as of Sep. 2025.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NYB Holdings's Pre-Tax Income for the six months ended in Sep. 2025 was $1.34 Mil. NYB Holdings's Revenue for the six months ended in Sep. 2025 was $0.09 Mil. Therefore, NYB Holdings's pretax margin for the quarter that ended in Sep. 2025 was 1,576.47%.

The historical rank and industry rank for NYB Holdings's Pretax Margin % or its related term are showing as below:


NYB's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63
* Ranked among companies with meaningful Pretax Margin % only.

NYB Holdings  (NAS:NYB) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

NYB Holdings Pretax Margin % Related Terms

NYB Holdings Pretax Margin % Historical Data

* Premium members only.

The historical data trend for NYB Holdings's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings Pretax Margin % Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
Pretax Margin %
0.00 1,576.47

NYB Holdings Semi-Annual Data
Sep24 Sep25
Pretax Margin % 0.00 1,576.47

NYB vs : Pretax Margin % Comparison

For the Biotechnology subindustry, NYB Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NYB Holdings Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NYB Holdings's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where NYB Holdings's Pretax Margin % falls into.


NYB Holdings Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

NYB Holdings's Pretax Margin for the fiscal year that ended in Sep. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=1.34/0.085
=1,576.47 %

NYB Holdings's Pretax Margin for the quarter that ended in Sep. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=1.34/0.085
=1,576.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 1,576.47% mean?
NYB Holdings (NYB) has a Pretax Margin % of 1,576.47% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NYB Holdings and its competitors.
Is NYB Holdings' Pretax Margin % too high?
NYB Holdings' current Pretax Margin % is 1,576.47%.
How does NYB Holdings' Pretax Margin % compare to ?
NYB Holdings' Pretax Margin % of 1,576.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NYB Holdings and its competitors. NYB Holdings's current Pretax Margin % is 1,576.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current Pretax Margin % of 1,576.47%. The current Pretax Margin % is 1,576.47%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For NYB Holdings (NYB), the current Pretax Margin % is 1,576.47% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.